Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05030792 · ClinicalTrials.gov registry record · NA

An Attention-Restorative Therapy (ART)-Based Virtual Reality Intervention to Address Cancer-Related Cognitive Impairments Among Breast Cancer Survivors

A NA study, sponsored by University of Michigan Rogel Cancer Center.

Completed
Registry status
NA
Development phase
30
Enrollment target

NCT05030792 is a NA study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 30 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05030792, a NA study, has completed, sponsored by University of Michigan Rogel Cancer Center.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target

Study Summary

This study is to assess the feasibility of using a Virtual Reality (VR) headset to provide nature-based Attention-Restorative Therapy (ART) as treatment for cognitive impairment in post-treatment cancer survivors. At ART's foundation is the belief that exposure to nature can improve attention by fully engaging a person in a safe and relaxing experience. This intervention uses a VR headset to expose the participant to nature while overcoming some potential barriers of nature-based interventions like access, physical ability, and bad weather. The goal of this study is to understand if people are willing to use the VR headsets to experience nature virtually, if they find it helpful with cancer-related cognitive impairments (CRCI) symptoms and if they are satisfied with using it. Participants will be asked to use self-management materials (weekly home practice logs, Oculus Go™ and online questionnaires) for 6 weeks. Investigators hope to use information from this small feasibility study to study the effectiveness of the intervention in a larger group of cancer survivors and ultimately to help cancer survivors struggling with cognitive impairments.

Interventions

  • OTHER Attention-restorative therapy (ART)-based virtual reality (VR)

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2021-10-26
Est. Completion 2022-05-16
Phase NA

What the Registry Record Tells You About NCT05030792

The ClinicalTrials.gov registry entry for NCT05030792 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Attention-restorative therapy (ART)-based virtual reality (VR) is the first listed.

NCT05030792 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05030792 about?

NCT05030792 is a clinical study titled "An Attention-Restorative Therapy (ART)-Based Virtual Reality Intervention to Address Cancer-Related Cognitive Impairments Among Breast Cancer Survivors". This study is to assess the feasibility of using a Virtual Reality (VR) headset to provide nature-based Attention-Restorative Therapy (ART) as treatment for cognitive impairment in post-treatment cancer survivors. At ART's foundation is the belief that exposure to nature can improve attention by ful...

What is the current status of trial NCT05030792?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2021-10-26. Estimated completion is 2022-05-16.

What interventions are being tested in trial NCT05030792?

The interventions under investigation include: Attention-restorative therapy (ART)-based virtual reality (VR) (OTHER).

Who is sponsoring clinical trial NCT05030792?

This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.